<DOC>
	<DOCNO>NCT00242866</DOCNO>
	<brief_summary>Nitric oxide ( NO ) likely involve development migraine headache . Nitric oxide synthase ( NOS ) important chemical involve production NO . Reduction NOS , therefore NO , may effective technique prevention migraine headache . GW274150 highly selective inhibitor NOS offer potential anti-inflammatory activity migraine novel mechanism action . The intent study investigate safety efficacy GW274150 prophylactic treatment migraine headache .</brief_summary>
	<brief_title>Use Of GW274150 In The Prophylactic Treatment Of Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Suffering migraine without aura . Migraine least one year , age onset prior 50 year . Consistent migraine headache time least 3 migraine headache attack less 15 day headache ( migraine nonmigraine ) per month three month prior Screening Visit maintain requirement baseline period . Able distinguish migraine headache attack discreet attack headache ( i.e . tensiontype headache ) . No clinically significant abnormality identify medical laboratory evaluation . A subject clinical abnormality laboratory parameter outside reference range may include doctor considers find introduce additional risk factor interfere study procedure . Written inform consent prior entry study . Females : ) nonchildbearing potential , b ) childbearing potential , negative pregnancy test screen , take adequate contraceptive measure . As result medical interview , physical examination screen investigation , doctor considers subject unfit study . Headache 15 day per month great three month ( 90 day ) precede Screening Visit . History alcohol , substance drug abuse within last year . Taken migraine prophylactic medication within 1 month Screening Visit . Uses opiate first line acute treatment migraine attack . History ergotamine , triptan , opioid , combination medication intake great than/equal 10 day per month regular basis great than/equal 3 month . History simple analgesic intake great than/equal 15 day per month great than/equal 3 month . Failed two adequate treatment migraine prophylaxis , failure define lack efficacy treatment duration least 8 week withdrawal treatment due treatment intolerance . Uncontrolled hypertension Screening Visit , define systolic blood pressure &gt; 140mmHg diastolic blood pressure &gt; 90mmHg . Taking cyclosporine and/or aminoglycosides . Evidence renal impairment calculate creatinine clearance &lt; 60ml/min clinically relevant find urinalysis . History drug allergy , opinion doctor , make subject unsuitable participation study . Concurrently participate another clinical study investigational drug trial participate within previous 3 month plan participate another drug device study time study ( screen followup ) previous exposure GW274150 Part 1 study . Felt risk noncompliance ( take study medication complete electronic diary ( ediary ) ) , doctor 's opinion . Pregnant nursing woman . History , risk factor , HIV , Hepatitis B Hepatitis C. Past present disease , judge doctor , may affect outcome study . These disease include , limited history liver renal disease 6 month prior screen . Clinically significant abnormality safety laboratory analysis Screening Visit , particularly abnormal liver pancreatic function test Screening Visit . Not cover social security .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Productivity</keyword>
	<keyword>Efficacy</keyword>
	<keyword>without aura</keyword>
	<keyword>iNOS</keyword>
	<keyword>Safety</keyword>
	<keyword>Nitric Oxide</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>GW274150</keyword>
	<keyword>aura</keyword>
	<keyword>Migraine</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>Quality Life</keyword>
</DOC>